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Abstract 58 
Objective: To examine the combined effects of common genetic variants associated with 59 
intraocular pressure (IOP) on primary open angle glaucoma (POAG) phenotype using a 60 
polygenic risk score (PRS) stratification. 61 
Design: Cross-sectional study. 62 
Participants: For the primary analysis, we examined the glaucoma phenotype of 2,154 POAG 63 
patients enrolled in the Australian and New Zealand Registry of Advanced Glaucoma 64 
(ANZRAG) including cases recruited from the UK. For replication, we examined an 65 
independent cohort of 624 early POAG patients. 66 
Methods: Using IOP genome-wide association study summary statistics, we developed a 67 
PRS derived solely from IOP associated variants and stratified POAG patients into three risk 68 
tiers. The lowest and highest quintiles of the score were set as the low and high risk groups 69 
respectively and the other quintiles as the intermediate risk group. 70 
Main Outcome Measures: Clinical glaucoma phenotype including maximum recorded IOP, 71 
age of diagnosis, number of family members affected by glaucoma, cup-to-disc ratio, visual 72 
field mean deviation, and treatment intensity. 73 
Results: There was a dose-response relationship between the IOP PRS and the maximum 74 
recorded IOP, with the high genetic risk group having a higher maximum IOP by 1.7 (SD 0.62) 75 
mmHg than the low genetic risk group (P = 0.006). Compared to the low genetic risk group, 76 
the high genetic risk group had a younger age of diagnosis by 3.7 (1.0) years (P < 0.001), 77 
more family members affected by 0.46 (0.11) members (P < 0.001), and higher rates of 78 
incisional surgery (odds ratio 1.5; 95% confidence interval 1.1 - 2.0; P = 0.007). There was no 79 
statistically significant difference in mean deviation. We further replicated the maximum IOP, 80 
number of family members affected by glaucoma and treatment intensity (number of 81 
medications) results in the early POAG cohort (P ≤ 0.01). 82 
Conclusions: The IOP polygenic risk score was positively correlated with maximum IOP, 83 
disease severity, need for surgery and number of family members. Genes acting via IOP 84 
mediated pathways, when considered in aggregate have clinically important and reproducible 85 
implications for glaucoma patients and their close family members.  86 
Glaucoma refers to a group of progressive optic neuropathies with a characteristic pattern of 87 
retinal ganglion cell death and visual field loss.1 Intraocular pressure (IOP) is currently the only 88 
proven modifiable risk factor for primary open angle glaucoma (POAG), in which the 89 
iridocorneal angle is open and there is no secondary cause of IOP elevation.2 Despite this, 90 
elevated IOP is not essential for the diagnosis of POAG, nor is it effective for screening for 91 
glaucoma.1,3 The current methods of IOP assessment are limited to the time of measurement 92 
and are a poor measure of an individual’s IOP profile, maximum and fluctuations. Additional 93 
IOP measurements are more informative for glaucoma management as both diurnal and long-94 
term IOP fluctuations have been reportedly associated with glaucoma progression.4,5 95 
 96 
Glaucoma is highly heritable and several genes with a Mendelian pattern of inheritance have 97 
been associated with POAG.6 Monogenic variants causing glaucoma are relatively rare but 98 
carry a high risk of developing the disease. Family-based genetic linkage analysis has 99 
identified three genes associated with Mendelian glaucoma; myocilin (MYOC), optineurin 100 
(OPTN) and TANK-binding kinase 1 (TBK1) genes.7–10 Pathogenic variants in the MYOC gene 101 
account for 2-4% of adult-onset POAG.10 The most common pathogenic variant in the MYOC 102 
gene in individuals of European ancestry (p.Gln368Ter) has a minor allele frequency of 0.13%, 103 
yet carries a significant risk of glaucoma with high IOP in those who carry it (in a population 104 
based setting odds ratio [OR] = 6.76 with 95% confidence interval [CI] of 4.05-11.29).11 In 105 
family-based studies, the penetrance of p.Gln368Ter to manifest POAG is reported at 106 
approximately 80% by the seventh decade of life.11 107 
 108 
IOP in the normal population is a polygenic trait, with recent large genome-wide association 109 
studies (GWAS) discovering more than one hundred common loci associated with IOP, 110 
accounting for 40% of the heritability.12–14 Khawaja et al. reported that these single nucleotide 111 
polymorphisms (SNPs) explained 17% of IOP variance in an independent clinical study, and 112 
9% in the UK biobank study which likely reflects the difference in IOP measurement methods.14 113 
In contrast to the aforementioned monogenic variants, each SNP contributes a very small 114 
effect size. For instance, variants in or near the genes TMCO1 and CAV2, two of the most 115 
strongly associated loci with IOP and glaucoma, are present in 10-15% of the population but 116 
account for a modest risk of glaucoma individually (OR 1.1 - 1.4).12–14 However, the combined 117 
effects of these common SNPs significantly affect the observed clinical phenotype.12  118 
 119 
To understand the impact of these common variants, we consider the total number of variants 120 
an individual is carrying multiplied by their effect size, to generate a weighted polygenic risk 121 
score (PRS).15 A genetic risk stratification may then be done by calculating an aggregate score 122 
of all the SNPs an individual has associated with a trait. For instance, a person with the 123 
majority of the discovered IOP variants (a high IOP PRS) is hypothesised to have a higher 124 
IOP than someone who has only a few. The PRS model of risk prediction has been used to 125 
stratify individualised disease risk in several medical conditions such as coronary artery 126 
disease, atrial fibrillation and breast cancer.16–18 Recently, a PRS derived from the known IOP 127 
variants has been reported to account for a higher risk of developing glaucoma;12 however, 128 
the influence of the IOP PRS on a wider range of glaucoma-related phenotypes has not been 129 
described. In this study, we aimed to characterise the clinical features of glaucoma patients 130 
with a high burden of IOP associated variants in a large national Australian glaucoma registry 131 
along with ethnically similar cases from the UK. 132 
Methods 133 
Study participants 134 
The study adhered to the tenets of the Declaration of Helsinki and followed the National Health 135 
and Medical Research Council statement of ethical conduct in research involving humans. 136 
Informed consent was obtained from all participants, and the study was approved by the 137 
Southern Adelaide Clinical Human Research Ethics Committee. 138 
 139 
The study participants were enrolled in the Australian and New Zealand Registry of Advanced 140 
Glaucoma (ANZRAG).19 The study includes both advanced and non-advanced glaucoma 141 
cases. Advanced glaucoma was defined by a Humphrey 24-2 visual field mean deviation (MD) 142 
< -15 dB in the worse eye, or loss of at least two of the central visual field points on the pattern 143 
deviation map.19 Non-advanced glaucoma was defined by optic nerve head changes with 144 
corresponding visual field defects consistent with glaucoma, but not fitting the aforementioned 145 
criteria. The study sample included additional ethnically matched advanced glaucoma cases 146 
recruited from the UK (contributed by AJL, CEW and NAV). Only patients of European 147 
ancestry with POAG were included to utilise the currently published IOP SNPs. Patients with 148 
variants in the known POAG genes (MYOC, OPTN and TBK1) were excluded. The highest 149 
IOP measurement recorded with Goldmann applanation tonometry by an experienced 150 
clinician before treatment of either eye for each participant was recorded. High tension 151 
glaucoma was defined as a maximum recorded IOP > 21 mmHg. Other data recorded included 152 
age at diagnosis, vertical cup-to-disc ratio (VCDR), and glaucoma surgery. Family history was 153 
self-reported and recorded for affected relatives up to the fourth degree. 154 
 155 
An independent cohort of early glaucoma patients enrolled in the Progression Risk Of 156 
Glaucoma; RElevant SNPs with Significant Association (PROGRESSA) study were then used 157 
for replication. Only participants with established perimetric glaucoma, defined by two 158 
consecutive reliable visual field examinations with Glaucoma Hemifield Test “Outside Normal 159 
Limits”, pattern standard deviation <5%, or a cluster of 3 contiguous points depressed <5% in 160 
the pattern standard deviation map, at least one of which is  <1%, were included. Data 161 
recorded included self-reported family history of glaucoma, maximum IOP recorded, VCDR, 162 
number of topical glaucoma medications and previous selective laser trabeculoplasty (SLT). 163 
 164 
Polygenic risk score 165 
The IOP derived PRS was comprised of 146 statistically independent genome-wide-significant 166 
SNPs (P value threshold at 5×10-8 and LD-clumping at r2 = 0.1) as reported previously 167 
(Supplementary Table 1).12 Briefly, SNPs influencing IOP were discovered by a GWAS of 168 
cornea-compensated IOP measured by Ocular Response Analyzer in participants of the UK 169 
Biobank study (N = 103,914).12,20 This was meta-analysed with GWAS results from the 170 
International Glaucoma Genetics Consortium (IGGC, N = 29,578) using the inverse variance 171 
weighted method (METAL software).21 A weighted PRS was then derived for each individual 172 
in the ANZRAG study cohort using PLINK (version 1.90 beta),22 taking into account the effect 173 
size of each SNP using the UK Biobank GWAS summary statistics. None of the study 174 
participants in ANZRAG or PROGRESSA were part of the discovery cohort. A percentile score 175 
was then derived within the ANZRAG and the PROGRESSA cohorts. We classified patients 176 
into three risk groups; the top 20% of the genetic risk score were classified as the high risk 177 
group; the middle 60% as the intermediate risk group; and the bottom 20% as the low risk 178 
group. Genotyping was done in several phases on either Illumina Omni1M, OmniExpress or 179 
HumanCoreExome arrays (Illumina, San Diego, CA, USA) as described previously.12 180 
Statistical analysis 181 
The Shapiro-Wilk test was used to assess for normality. Analysis of variance of continuous 182 
variables by PRS groups was done using Kruskal–Wallis test. Count and categorical variables 183 
were compared using Pearson's chi-squared test. For two-group comparisons, the Mann-184 
Whitney U test was used. Logistic regression models were fitted for binary outcomes and 185 
negative binomial regression was used for count data (number of family members affected). 186 
All analysis was done using R (version 3.5.1, RCore Team, Austria).23 The significance level 187 
(alpha) was set at 0.05. 188 
Results 189 
A total of 2,154 eligible POAG patients from ANZRAG with mean age at recruitment of 77.4 190 
(SD 13.2) years were included. The majority of the study cohort (N = 1,664; 77%) had 191 
advanced glaucoma as defined above. This included 381 cases recruited from the UK (N = 192 
290 from Southampton and N = 91 Liverpool) who were ethnically matched to the rest of the 193 
cohort. A summary of the glaucoma phenotype across the three genetic risk groups is 194 
summarised in Table 1. 195 
 196 
The high IOP genetic risk group had a significantly higher maximum IOP by 1.3 mmHg (95%CI: 197 
0.32 - 2.7 mmHg; P = 5.5x10-3) compared to the intermediate and low genetic risk groups. The 198 
maximum IOP was not statistically significantly different in the intermediate group relative to 199 
the low risk group (mean difference of 0.54 mmHg, 95% CI -1.5 - 0.47 mmHg; P = 0.08). 200 
Similarly, the high genetic risk group was more likely to present as high tension glaucoma, 201 
defined by a maximum IOP above 21 mmHg (OR = 1.9; 95% CI 1.3 - 2.8; P = 7.9x10-4 relative 202 
to the low-risk group). Further analysis by decile groups of the IOP PRS shows a continuous 203 
variant dose-response relationship between higher IOP PRS and maximum IOP, signifying 204 
the cumulative effects of the common IOP variants (Figure 1A). 205 
 206 
The mean age of glaucoma diagnosis was significantly different across the genetic risk groups 207 
(P = 1.3x10-4). The high genetic risk group were diagnosed with glaucoma on average 2.2 (SD 208 
0.80) years earlier than the intermediate group (P = 5.5x10-3) and 3.7 (SD 1.0) years than the 209 
low genetic risk group (2.4x10-4). The high risk group were more likely to have family members 210 
affected by glaucoma relative to the low risk group (OR = 1.6, 95% CI 1.2 - 2.1. P = 1.1x10-3). 211 
The number of self-reported family members affected by glaucoma was also higher in the high 212 
IOP PRS group compared to the intermediate (mean 0.29, SD 0.1, P = 5.2x10-3) and low risk 213 
groups (mean 0.46, SD 0.11, P = 1.8x10-4). Furthermore, there was a linear relationship 214 
between the IOP PRS and the number of family members affected by glaucoma which 215 
highlights the importance of these variants and their impact on the development of glaucoma 216 
(Figure 1B). 217 
 218 
There was no significant difference between the Humphrey visual field mean deviation 219 
between the IOP PRS groups P = 0.18). However, the high genetic risk group were more likely 220 
to require an incisional surgery for the management of their glaucoma relative to the 221 
intermediate and low risk groups (OR = 1.3, 95% CI = 1.0 - 1.6; P = 0.049 and OR = 1.5; 95% 222 
CI  = 1.1 - 2.0; P = 7.9x10-3 respectively). Further, the high IOP PRS group were more likely 223 
to require bilateral incisional surgeries than the intermediate and low risk groups (OR = 1.4, 224 
95% CI = 1.0 - 1.8; P = 0.02). 225 
 226 
For replication, we stratified an independent cohort of early perimetric POAG patients (N = 227 
624), with an average age of 69.5 (10) years, into three risk groups based on the same 228 
absolute numerical IOP PRS cut-off used above. There was a similar association of increasing 229 
maximum IOP, number of family members affected, and treatment intensity (Table 2 and 230 
Figure 2). The high risk group had more than twice as many family members affected as the 231 
low risk group, and were more likely to require more intensive medical therapy to control their 232 
disease (P ≤ 0.01).  233 
Discussion 234 
Common genetic variants associated with both glaucoma and IOP have been identified via 235 
genome-wide association studies. Genetic risk score stratification can be used to estimate the 236 
combined effect size of these variants on the patient. In this study, glaucoma patients in the 237 
high IOP genetic risk group had a higher maximum (pre-treatment) IOP, younger age of 238 
glaucoma diagnosis, and were more likely to require incisional surgery to control their disease 239 
than those in the intermediate or low IOP genetic risk groups. We have further replicated these 240 
results in an independent cohort of early glaucoma patients and observed a similar association 241 
with the higher genetic risk group requiring more intensive medical therapy for glaucoma 242 
management. 243 
 244 
Interestingly, despite the clinically modest difference in the maximum IOP between the high 245 
and low IOP genetic risk groups (between 1-2 mmHg in two independent cohorts), we 246 
observed a stronger relationship in treatment intensity. In the ANZRAG cohort, the incisional 247 
surgery rate was 50% in the high genetic risk group compared to 38% in the low risk group. 248 
Similarly, in the early glaucoma cohort, 38% of the high genetic risk group required 2 or more 249 
medications or SLT for glaucoma management compared to 23% in the low genetic risk group. 250 
Thus, IOP genetic risk variants and stratification may offer further insight into an individual's 251 
chronic exposure to higher IOP than sporadic clinic measurements. Further, these risk variants 252 
confer increased risk of developing POAG in carriers,12 thus patients with higher polygenic risk 253 
scores had significantly more family members affected by glaucoma. 254 
 255 
Previous studies of common genetic variants in glaucoma have focused on individual SNPs 256 
only. TMCO1 was one of the earliest reported genes to be associated with POAG in common 257 
variant studies, and remains one of the most strongly associated variants with IOP and 258 
POAG.12,14,24 A variant in TMCO1 gene is reportedly associated with conversion from ocular 259 
hypertension to glaucoma in non-Hispanic whites25 In another study, individuals homozygous 260 
for a variant near TMCO1 were reported to have a younger age of POAG onset.26 However, 261 
the clinical utility of genetic risk scores is expanding due to the accelerated discovery of 262 
disease-associated loci as larger genome-wide association studies are conducted. While early 263 
studies on using genetic risk scores for POAG were limited,27,28 Macgregor et al. have recently 264 
reported an IOP based genetic risk score accounting for a significant risk of developing 265 
glaucoma (OR = 5.6 in the highest decile of the score relative to the lowest).12  266 
 267 
Conversely, the effects of Mendelian variants on glaucoma phenotype have been well 268 
described. Pathogenic variants in the MYOC gene are most commonly associated with high 269 
IOP and more advanced disease.29 In contrast, duplications and triplications involving TBK1 270 
and missense variants in OPTN cause familial normal tension glaucoma, and are typically not 271 
found in high tension glaucoma.7–9 While these genes are important in familial glaucoma and 272 
highly predictive of disease risk, they are a relatively rare cause of POAG in the general 273 
population. Thus, genetic risk stratification using common variants of IOP is more widely 274 
applicable to most POAG patients. Our results show that the cumulative effect of IOP-275 
associated genetic variants may predict an individual's lifetime IOP exposure, and support the 276 
utility of genetic risk scores in POAG monitoring. Further, PRS risk stratification can be done 277 
before the clinical presentation of the disease, and therefore may be useful for identifying high-278 
risk individuals for screening. To our knowledge, this is the first study to detail the clinical 279 
glaucoma phenotype based on the combined effect of common IOP variants. 280 
 281 
This study has several strengths. We utilised the large UK Biobank cohort to derive a genetic 282 
risk score of corneal compensated IOP. Our study cohort was also independent allowing 283 
validation of the discovered variants. We have further replicated our findings in another 284 
independent POAG cohort with mild glaucoma allowing further generalisability across the 285 
glaucoma severity spectrum. Our study has also some limitations. Genetic risk scores are 286 
limited by the genetic pool of the discovery cohort. Our results are limited to the ethnicities of 287 
the European ancestry individuals of the UK Biobank study which matched our prediction 288 
target cohort. Validation is needed in other ethnicities. We have only used SNPs that reached 289 
genome-wide significance in the GWAS to calculate the PRS. While the inclusion of additional 290 
SNPs would include further low-impact susceptibility SNPs, it would also introduce further 291 
‘noise’ to the PRS and may not improve risk stratification.30 292 
 293 
In conclusion, our IOP PRS correlates with the maximum recorded IOP and glaucoma 294 
severity of POAG patients in a national glaucoma registry. Our result supports the clinical 295 
utility of PRS in POAG risk stratification. 296 
 297 
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Figure legends: 303 
 304 
Figure 1. A continuous variant dose-response relationship between IOP PRS and (A) the 305 
maximum recorded IOP in the ANZRAG cohort (P = 1.9x10-3 for linear model trend); (B) the 306 
mean number of family members affected by glaucoma (P = 1.3x10-5 for negative binomial 307 
generalised linear model trend). The squares represent the mean values for each PRS decile 308 
group, and the error bars represent the 95% confidence interval of the mean. The grey line is 309 
the line of best fit with the 95% confidence interval lightly shaded around the line. 310 
IOP: intraocular pressure; PRS: polygenic risk score. 311 
 312 
Figure 2. Replication of the (A) maximum IOP recorded (P = 5.0x10-4 for one-way analysis of 313 
variance) and (B) the number of family members affected by glaucoma (P = 1.0x10-3 for one-314 
way analysis of variance) in an independent cohort of early POAG patients (N = 624). The 315 
squares represent the mean values for each PRS group, and the error bars represent the 95% 316 
confidence interval of the mean. 317 
IOP: intraocular pressure; PRS: polygenic risk score; POAG: primary open angle glaucoma. 318 
 319 
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Table 1: Summary of the glaucoma phenotype across genetic risk groups in ANZRAG 
 
 Low Intermediate High p 
Number 410 1313 431 - 
Gender, male (%)    192 (46.8)    622 (47.4)    185 (43.0) 0.3 
HTG (%)    251 (74.3)    867 (79.1)    298 (84.7) 0.003 
Age of diagnosis, years  62.90 (15.32)  61.39 (14.16)  59.16 (13.80) <0.001 
Family members affected   0.99 (1.56)   1.16 (1.53)   1.45 (1.89) 0.001 
Maximum recorded IOP, mmHg  25.54 (9.17)  26.08 (8.63)  27.25 (9.14) 0.005 
VCDR   0.87 (0.11)   0.86 (0.12)   0.87 (0.13) 0.3 
Visual field MD, dB -16.87 (9.04) -16.12 (9.15) -16.91 (9.25) 0.2 
Incisional surgery rate* (%)    151 (39.8)    507 (43.7)    186 (49.5) 0.03 
Bilateral incisional surgery* rate (%) 65 (17.2)    259 (22.3)    100 (26.6) 0.007 
 
Low risk group represents the first quintile of the IOP genetic risk score and the high risk is 
the highest quintile. Values displayed are mean (standard deviation) for continuous variables 
and N (%) for categorical variables. P values represent the statistical significance of the 
analysis of variance (difference between any two groups) for continuous variables (Kruskal–
Wallis test) or Chi-squared test for categorical variables. HTG is defined by a maximum IOP 
>21 mmHg. 
HTG: High tension glaucoma; IOP: intraocular pressure; VCDR: vertical cup-to-disc ratio; 
MD: mean deviation. 
* The majority of the incisional surgeries in this dataset were trabeculectomies. Other 
surgeries include tube shunt surgery, deep sclerectomy and two cases of Xen Gel implants . 
 
Table 1
Table 2: Summary of the glaucoma phenotype across genetic risk groups in the replication 
cohort (PROGRESSA) 
 
Variable Low Intermediate High p 
Number 144 378 102 - 
Gender, male    68 (47.2)   159 (42.1) 37 (36.3) 0.228 
Number of family members affected  0.60 (1.21)  0.88 (1.19)  1.27 (1.81) 0.001 
Maximum recorded IOP, mmHg 19.31 (5.36) 21.08 (5.80)  21.03 (5.20) <0.001 
VCDR  0.73 (0.10)  0.74 (0.10)  0.72 (0.10) 0.119 
Visual field MD, dB -3.17 (2.94) -3.35 (3.10) -2.79 (2.73) 0.442 
Number of glaucoma drops or SLT*  1.06 (1.18)  1.36 (1.35)   1.35 (1.26) 0.033 
Required 2 or more medications or SLT*    33 (22.9)   133 (35.2) 39 (38.2) 0.013 
 
Risk group stratification is based on IOP genetic risk score cut-offs as calculated and used in 
the primary cohort (ANZRAG). Values displayed are mean (standard deviation) for 
continuous variables and N (%) for categorical variables. P values represent the statistical 
significance of the analysis of variance for continuous variables (Kruskal–Wallis test) or Chi-
squared test for categorical variables. 
* SLT was counted as equivalent to 1 glaucoma medication. 
IOP: intraocular pressure; VCDR: vertical cup-to-disc ratio; MD: mean deviation; SLT: 
selective laser trabeculoplasty. 
 
Table 2
SNP A1 A2 BETA SE P
rs10918274 T C 0.3327 0.0192 3.68E-67
rs9913911 A G 0.2122 0.0132 2.16E-58
rs10281637 T C -0.2235 0.0141 6.75E-57
rs2472493 A G -0.1914 0.0127 3.02E-51
rs9853115 A T -0.1786 0.0128 1.80E-44
rs1044864 A G -0.2145 0.0169 7.82E-37
rs28500712 A G 0.1791 0.0145 5.70E-35
rs12377624 C G -0.1542 0.013 1.23E-32
rs2022945 A G -0.2146 0.0188 2.49E-30
rs1579050 A G -0.1346 0.0127 3.90E-26
rs7123436 A G 0.1568 0.0158 2.60E-23
rs11217863 A G 0.1966 0.0199 4.76E-23
rs2745572 A G 0.1329 0.0137 3.57E-22
rs55892100 A G 0.1296 0.0134 4.37E-22
rs28470731 T C -0.1182 0.0128 2.55E-20
rs4775427 T C 0.1096 0.0126 2.88E-18
rs9405157 T C 0.1371 0.0158 4.69E-18
rs10838681 A G 0.1225 0.0142 4.82E-18
rs4496939 A G -0.1155 0.0136 2.01E-17
rs9608740 A C -0.147 0.0174 2.41E-17
rs17687006 T C -0.1239 0.0147 4.06E-17
rs6478750 T C 0.1098 0.0131 4.68E-17
rs34952318 A G -0.2669 0.0322 1.16E-16
rs9494457 A T -0.1076 0.0131 2.35E-16
rs12147852 A G -0.1218 0.0149 3.44E-16
rs10819187 A G -0.1581 0.0195 4.55E-16
rs1001989 T C 0.1072 0.0132 4.93E-16
rs11795066 A G 0.1035 0.0129 9.76E-16
rs4141194 A C 0.1137 0.0142 9.94E-16
rs11651314 T C 0.1482 0.0187 2.36E-15
rs7924522 A C 0.1055 0.0134 3.10E-15
rs141377403 C G -0.4773 0.0607 3.62E-15
rs62520914 A G 0.199 0.0253 4.17E-15
rs6781336 A G 0.1056 0.0135 6.37E-15
rs4133395 T G -0.099 0.0129 1.86E-14
rs746491 A C 0.1214 0.0158 1.90E-14
rs2279948 A G 0.17 0.0224 3.65E-14
rs1874458 A G -0.0984 0.0131 7.29E-14
rs1558225 A G -0.116 0.0156 1.06E-13
rs78447765 T C -0.1776 0.0242 2.00E-13
rs12444539 A T -0.1755 0.0239 2.21E-13
rs31918 T C -0.1004 0.0139 4.54E-13
rs3743860 T C 0.0974 0.0135 5.63E-13
rs76020419 T G -0.2591 0.036 6.10E-13
rs13109331 T G 0.1131 0.0158 7.37E-13
rs7338461 A G 0.0896 0.0125 8.22E-13
rs35705029 A T -0.0979 0.0138 1.20E-12
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rs73111535 A C -0.1847 0.026 1.21E-12
rs10800149 A C 0.0946 0.0133 1.27E-12
rs113985657 T C 0.1272 0.0179 1.28E-12
rs7951180 A G 0.1038 0.0146 1.30E-12
rs5756813 T G -0.0899 0.0128 2.25E-12
rs3778523 T C 0.0964 0.0138 2.46E-12
rs756481 A G 0.2062 0.0296 3.14E-12
rs10852918 A G -0.0892 0.0129 4.31E-12
rs4959631 T C -0.089 0.0129 5.95E-12
rs12413181 A G 0.1527 0.0222 6.58E-12
rs113845710 C G 0.1188 0.0174 7.61E-12
rs327716 A G 0.0865 0.0127 1.04E-11
rs6546486 A T -0.0863 0.0128 1.38E-11
rs12045227 A G 0.1063 0.0158 1.61E-11
rs4836547 C G -0.0823 0.0123 1.89E-11
rs77064891 T C 0.3133 0.0467 1.99E-11
rs4434990 A G 0.1283 0.0191 2.04E-11
rs7936821 C G -0.1258 0.0188 2.34E-11
rs67943620 A G 0.1157 0.0177 6.23E-11
rs66724425 T C -0.0942 0.0145 7.72E-11
rs1501086 A T -0.1141 0.0176 8.29E-11
rs11752730 C G 0.085 0.0131 8.89E-11
rs113542380 A G 0.1596 0.0246 9.55E-11
rs4955665 T C 0.0842 0.013 9.85E-11
rs73506198 T C -0.1449 0.0225 1.10E-10
rs7534738 A C 0.0846 0.0131 1.15E-10
rs1755056 A C -0.0863 0.0134 1.21E-10
rs2188836 T C 0.0831 0.0129 1.35E-10
rs72902139 T C -0.1388 0.0216 1.36E-10
rs1746483 C G 0.0807 0.0127 1.80E-10
rs3013274 A G -0.0834 0.0131 1.81E-10
rs28613932 A G -0.0804 0.0126 1.82E-10
rs61755579 T C -0.2441 0.0383 1.94E-10
rs147699531 T G 0.1303 0.0205 2.00E-10
rs8176747 C G -0.1628 0.0258 2.75E-10
rs73191227 A G -0.17 0.027 3.16E-10
rs12123086 A G -0.1238 0.0197 3.49E-10
rs1970719 T C -0.1203 0.0192 3.97E-10
rs1633715 T C 0.19 0.0305 4.70E-10
rs16837021 T C -0.0944 0.0152 4.99E-10
rs76945759 A G -0.1487 0.024 5.45E-10
rs35174414 T C -0.0791 0.0128 7.12E-10
rs715338 A G -0.0797 0.013 7.73E-10
rs4672075 C G -0.0757 0.0124 1.12E-09
rs16856911 C G 0.1716 0.0282 1.21E-09
rs113968938 T C -0.1009 0.0166 1.30E-09
rs4074961 T C 0.0784 0.0129 1.30E-09
rs4629237 A C 0.0797 0.0131 1.30E-09
rs73220177 A G -0.1512 0.0252 1.87E-09
rs11530907 C G 0.1199 0.02 2.08E-09
rs760444 A G -0.0954 0.0159 2.10E-09
rs10820755 A C 0.0788 0.0133 3.07E-09
rs35381200 T C -0.0772 0.013 3.10E-09
rs57435966 T C -0.1318 0.0223 3.65E-09
rs11065979 T C -0.0779 0.0132 3.98E-09
rs12356830 T C 0.0799 0.0136 4.02E-09
rs150329092 A G 0.2168 0.0369 4.36E-09
rs60147425 A G 0.2881 0.0491 4.44E-09
rs111307712 T C -0.1167 0.0199 4.79E-09
rs3791979 T C -0.0788 0.0135 4.91E-09
rs2163870 A G 0.0741 0.0127 6.15E-09
rs3134954 T C 0.1057 0.0182 6.74E-09
rs4627617 A G -0.0975 0.0168 6.93E-09
rs11079868 A G -0.0742 0.0128 7.16E-09
rs2048047 T C 0.0866 0.015 7.16E-09
rs10043368 A G -0.0732 0.0127 7.70E-09
rs4132172 T C -0.0833 0.0145 8.40E-09
rs10869665 T C -0.0815 0.0142 9.90E-09
rs2226566 A T 0.0932 0.0163 9.92E-09
rs6095946 T C -0.075 0.0131 1.01E-08
rs2294239 A G 0.0739 0.0129 1.06E-08
rs7519368 A T -0.0815 0.0143 1.09E-08
rs35638741 A C 0.0733 0.0129 1.20E-08
rs6554074 T G -0.0708 0.0124 1.21E-08
rs11242708 T C -0.1036 0.0182 1.23E-08
rs9463095 A G 0.1023 0.018 1.32E-08
rs10185855 A G 0.0727 0.0129 1.51E-08
rs73296215 T C 0.3162 0.0561 1.69E-08
rs72959706 A G 0.1384 0.0246 1.89E-08
rs59427698 A G -0.0823 0.0146 1.90E-08
rs6065171 T C 0.0709 0.0126 1.91E-08
rs1381486 T G -0.1498 0.0267 2.00E-08
rs6952464 T C -0.0751 0.0134 2.05E-08
rs2071280 C G 0.0892 0.0159 2.09E-08
rs163524 A C 0.0935 0.0167 2.11E-08
rs12786875 A G 0.0824 0.0147 2.18E-08
rs883245 A G 0.0736 0.0132 2.53E-08
rs10767734 T C 0.0724 0.013 2.73E-08
rs41506447 T G -0.0983 0.0177 2.91E-08
rs72670480 A G 0.092 0.0166 3.23E-08
rs215543 A G -0.0846 0.0154 3.91E-08
rs76778164 A C 0.0917 0.0167 4.03E-08
rs9419741 A G -0.0723 0.0132 4.27E-08
rs10901553 A G 0.0995 0.0182 4.30E-08
rs6476827 C G -0.0743 0.0136 4.33E-08
rs59702603 A G -0.1739 0.0318 4.50E-08
rs12548673 A C -0.0776 0.0142 4.81E-08
rs56401620 A G 0.0973 0.0178 4.86E-08
rs56152426 A G 0.0935 0.0171 4.99E-08
